SCHEMBL3551389

SCHEMBL3551389

Cc1cccn2c(-c3nc(N[C@@H](C)c4ccccc4)nc4[nH]cnc34)cnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
RPS6KB1 P23443 4/20 0.37
TP53 P04637 2/20 0.37
ATP1A1 P05023 4/20 0.35
ATP1B1 P05026 4/20 0.35
ATP1A3 P13637 4/20 0.35
ATP1B2 P14415 4/20 0.35
ATP1A2 P50993 4/20 0.35
ATP1B3 P54709 4/20 0.35
FXYD2 P54710 4/20 0.35
ATP1A4 Q13733 4/20 0.35
HDAC8 Q9BY41 1/20 0.34
PDE9A O76083 1/20 0.34
LDHA P00338 2/20 0.34
LDHB P07195 2/20 0.34
HTR7 P34969 1/20 0.33
FLT1 P17948 1/20 0.33
IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3556570 0.85 LMNA (0.40) SMN1; SMN2LMNAHSD17B10RPS6KB1ATP1A1
SCHEMBL3551237 0.81 TP53 (0.38) SMN1; SMN2TP53ATP1A1ATP1B1ATP1A3
SCHEMBL3554499 0.80 IGF1R (0.39) SMN1; SMN2RPS6KB1TP53ATP1A1ATP1B1
SCHEMBL3548594 0.80 MAPK14 (0.40) SMN1; SMN2HSD17B10RPS6KB1TP53ATP1A1
SCHEMBL3552537 0.80 TP53 (0.39) SMN1; SMN2RPS6KB1TP53ATP1A1ATP1B1
SCHEMBL3551921 0.80 TP53 (0.43) SMN1; SMN2RPS6KB1TP53ATP1A1ATP1B1
SCHEMBL3552661 0.80 TP53 (0.43) SMN1; SMN2LMNATP53HDAC8LDHA
SCHEMBL3555836 0.79 TP53 (0.38) SMN1; SMN2RPS6KB1TP53ATP1A1ATP1B1
SCHEMBL3549226 0.79 HDAC6 (0.39) SMN1; SMN2RPS6KB1TP53ATP1A1ATP1B1
SCHEMBL3550460 0.78 IGF1R (0.43) SMN1; SMN2RPS6KB1TP53ATP1A1ATP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101048406-B Novel substituted imidazole derivatives BANYU PHARMA CO LTD 2010-12-22 CN disclosed
US-7718801-B2 Substituted imidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-05-18 US disclosed
US-20080070894-A1 Novel Substituted Imidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
CN-101048406-A Novel substituted imidazole derivatives BANYU PHARMA CO LTD (JP) 2007-10-03 CN disclosed
EP-1790650-A1 NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070894-A1 Novel Substituted Imidazole Derivative PLK1, CDK1, CDK11A SMN1; SMN2 3452/4885LMNA 2017/4885HSD17B10 3515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.